<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04486742</url>
  </required_header>
  <id_info>
    <org_study_id>IRB 2019-2560</org_study_id>
    <nct_id>NCT04486742</nct_id>
  </id_info>
  <brief_title>Brief Cognitive Behavioral Therapy to Treat Itch Rumination &quot;Itch CBT&quot; in Eczema</brief_title>
  <official_title>Brief Cognitive Behavioral Therapy to Treat Itch Rumination &quot;Itch CBT&quot; in Eczema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ann &amp; Robert H Lurie Children's Hospital of Chicago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to adapt cognitive behavior therapy (CBT) to improve itch&#xD;
      in children with eczema.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eczema is characterized by chronic itch. Many children develop a chronic focus (rumination)&#xD;
      on their itch. Rumination is a maladaptive method of responding to distress, in which the&#xD;
      individual thinks obsessively about the source of distress. The rumination on chronic itch in&#xD;
      eczema can have detrimental effects on one's quality of life, as well as induce significant&#xD;
      anxiety about when itch will return, how long it will last, and how it will affect physical&#xD;
      and social functioning.&#xD;
&#xD;
      Cognitive behavior therapy (CBT) is a frontline treatment for rumination, as it focuses on&#xD;
      teaching strategies so that the individual can examine distressing thoughts objectively and&#xD;
      determine their validity, replace negative thinking patterns with more adaptive thought&#xD;
      patterns, and increase the individual's awareness to their problematic thought patterns.&#xD;
      Additionally, CBT helps the individual to implement behavioral strategies to cope with&#xD;
      possibly anxiety-inducing situations, such as scratching while trying to go to sleep.&#xD;
&#xD;
      The investigators hypothesize that an Itch CBT intervention is an effective,&#xD;
      non-medication-based, easy to implement strategy to improve itch in children with eczema.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Itch Severity Numerical Rating Scale</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Numerical rating scale to assess itch severity, scale of 0-10, higher score means higher itch severity and worse outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Children's Dermatology Life Quality Index</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Questionnaire to assess impact of eczema on quality of life.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Itch Rumination Questionnaire</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Questionnaire to assess common fear and anxiety around itch</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PROMIS Anxiety and Depression</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Questionnaire to assess anxiety and depression symptoms in pediatric populations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PROMIS Pediatric Itch - Short Form 1 (2+6)</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>Questionnaire to assess level and severity of itch and common disturbances due to itch (social, emotional, physical)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Itch CBT Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to the Itch CBT Arm will participate in 4 weekly telehealth sessions with a therapist to address common areas of anxiety related to atopic dermatitis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Care Arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants randomized to the Usual Care Arm of the study will receive standard of care eczema educational materials that are typically provided by their health care provider after a clinic (or telehealth) visit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Itch CBT</intervention_name>
    <description>Telemedicine CBT sessions with a therapist to address atopic dermatitis related concerns.</description>
    <arm_group_label>Itch CBT Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Moderate to severe atopic dermatitis [assessed by Patient Oriented Eczema Measure&#xD;
             (POEM)score of &gt;-8 OR NRS itch score of &gt;= 4].&#xD;
&#xD;
          -  English speaking.&#xD;
&#xD;
          -  Currently receiving treatment at Lurie Children's Hospital for atopic dermatitis.&#xD;
&#xD;
          -  Parent or guardian available to participate in protocol.&#xD;
&#xD;
          -  Have sufficient technology (e.g., cell phone, computer, tablet, etc.) that can be used&#xD;
             to access Zoom conference technology for telemedicine visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to comprehend and complete questionnaires.&#xD;
&#xD;
          -  History of intellectual disability or psychosis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amy Paller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michelle Taddeo, MPH</last_name>
    <phone>3125031469</phone>
    <email>michelle.taddeo@northwestern.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Lurie Children's Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Taddeo, MPH</last_name>
      <phone>312-503-1469</phone>
      <email>michelle.taddeo@northwestern.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>July 14, 2020</study_first_submitted>
  <study_first_submitted_qc>July 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2020</study_first_posted>
  <last_update_submitted>March 1, 2021</last_update_submitted>
  <last_update_submitted_qc>March 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Amy Paller</investigator_full_name>
    <investigator_title>Study Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Pediatric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 24, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/42/NCT04486742/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 19, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/42/NCT04486742/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

